Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Capital Expenditures (2022 - 2026)

HeartSciences' Capital Expenditures history spans 4 years, with the latest figure at -$9476.0 for Q1 2026.

  • For Q1 2026, Capital Expenditures changed N/A year-over-year to -$9476.0; the TTM value through Jan 2026 reached $39323.0, down 33.96%, while the annual FY2025 figure was $3157.0, 95.1% down from the prior year.
  • Capital Expenditures reached -$9476.0 in Q1 2026 per HSCS's latest filing, down from $48799.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $48799.0 in Q2 2024 to a low of -$9476.0 in Q1 2026.
  • Average Capital Expenditures over 4 years is $9160.9, with a median of $6078.5 recorded in 2022.
  • Peak YoY movement for Capital Expenditures: plummeted 32.25% in 2023, then skyrocketed 542.77% in 2024.
  • A 4-year view of Capital Expenditures shows it stood at $7247.0 in 2022, then tumbled by 73.06% to $1952.0 in 2023, then soared by 2399.95% to $48799.0 in 2024, then tumbled by 119.42% to -$9476.0 in 2026.
  • Per Business Quant, the three most recent readings for HSCS's Capital Expenditures are -$9476.0 (Q1 2026), $48799.0 (Q2 2024), and $8794.0 (Q1 2024).